| Literature DB >> 30952607 |
Jingxia Wu1, Sicong Ma2, Roger Sandhoff3, Yanan Ming4, Agnes Hotz-Wagenblatt5, Vincent Timmerman6, Nathalie Bonello-Palot7, Beate Schlotter-Weigel8, Michaela Auer-Grumbach9, Pavel Seeman10, Wolfgang N Löscher11, Markus Reindl11, Florian Weiss12, Eric Mah13, Nina Weisshaar14, Alaa Madi14, Kerstin Mohr1, Tilo Schlimbach1, Rubí M-H Velasco Cárdenas1, Jonas Koeppel1, Florian Grünschläger1, Lisann Müller1, Maren Baumeister1, Britta Brügger15, Michael Schmitt16, Guido Wabnitz17, Yvonne Samstag17, Guoliang Cui18.
Abstract
Patients with the neurological disorder HSAN-I suffer frequent infections, attributed to a lack of pain sensation and failure to seek care for minor injuries. Whether protective CD8+ T cells are affected in HSAN-I patients remains unknown. Here, we report that HSAN-I-associated mutations in serine palmitoyltransferase subunit SPTLC2 dampened human T cell responses. Antigen stimulation and inflammation induced SPTLC2 expression, and murine T-cell-specific ablation of Sptlc2 impaired antiviral-T-cell expansion and effector function. Sptlc2 deficiency reduced sphingolipid biosynthetic flux and led to prolonged activation of the mechanistic target of rapamycin complex 1 (mTORC1), endoplasmic reticulum (ER) stress, and CD8+ T cell death. Protective CD8+ T cell responses in HSAN-I patient PBMCs and Sptlc2-deficient mice were restored by supplementing with sphingolipids and pharmacologically inhibiting ER stress-induced cell death. Therefore, SPTLC2 underpins protective immunity by translating extracellular stimuli into intracellular anabolic signals and antagonizes ER stress to promote T cell metabolic fitness.Entities:
Keywords: CD8+ T cells; ER stress; HSAN-I; SPTLC2; neurological diseases
Mesh:
Substances:
Year: 2019 PMID: 30952607 PMCID: PMC6531359 DOI: 10.1016/j.immuni.2019.03.005
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745